Preserve personalised induced pluripotent stem cells as a renewable platform for future research and regulated medical applications.
Stem cells can replicate themselves and develop into specialized cell types, though their potential varies. For example, blood-forming stem cells mainly develop into blood cells, while neural stem cells produce nerve tissue. Pluripotent stem cells have broader potential, capable of developing into nearly any tissue type in the human body. Induced pluripotent stem cells (iPSCs) are created by reprogramming adult cells, such as blood or skin cells, into this pluripotent state.
Unlike embryonic stem cells, which are derived from early-stage embryos and raise ethical considerations, or donor-derived cells, which carry compatibility risks, iPSCs are produced in a laboratory by reprogramming an individual’s own adult cells, such as blood or skin cells, without using an embryo. Once established, an iPSC line can be expanded and studied as a renewable cell source. Being genetically related to the patient doesn’t guarantee every iPSC-derived product is safe or immune-compatible. Any inherited genetic condition will be carried into the iPSCs, so additional assessment or genetic correction may be needed before therapeutic use.
Adult cells can be collected from sources such as blood or skin. Selected cells are then exposed to specific reprogramming factors under controlled laboratory conditions. These factors return the cells to a pluripotent state. Successfully reprogrammed cells are expanded to establish an iPSC line. The iPSC line can then be cryopreserved for future research or regulated therapies.
Step 1
The intended service details, source-cell collection process, permitted uses, storage period and consent requirements are reviewed with the customer.
Adult cells are collected from an agreed source, such as a peripheral blood sample or skin cells.
The selected adult cells are reprogrammed in the laboratory to generate candidate iPSC colonies.
Candidate colonies are expanded and assessed to confirm their identity, pluripotent characteristics, sterility and genetic quality.
Qualified iPSC lines are frozen under controlled conditions, assigned a unique identifier and transferred into monitored cryogenic storage.
The customer receives documentation identifying what was generated, tested and placed into storage.
iPSCs can develop into many specialised cell types, researchers are studying their potential to generate cells associated with the heart, nervous system, blood, immune system and other tissues.
iPSCs can be created from adult cells collected from an individual.
Once an iPSC line is established, the cells may be expanded to create additional research or therapeutic material.
Under controlled conditions, iPSCs may be directed to develop into different specialised cell types.
Patient-specific iPSCs may be used in areas such as disease modelling, drug research and the development of future personalised cell technologies.
Undifferentiated iPSCs are not injected directly as a general treatment. Cells intended for clinical use must be differentiated, purified, characterised and tested before administration. Important risks include genetic abnormalities, contamination, unintended cell development and tumour formation. These risks must be addressed through regulated research and manufacturing.
Patient-derived iPSCs may be developed into relevant cell types so researchers can study how a disease develops.
Researchers may use iPSC-derived cells to investigate how cells respond to potential medicines.
Because iPSCs can be generated from an individual’s cells, they may help researchers study differences between patients.
Scientists are exploring whether iPSC-derived cells could eventually replace or repair damaged cells and tissues.
iPSCs are also being investigated as a renewable starting material for producing immune cells such as natural killer cells and specialised T cells.
Reach us for banking enquiries, sample retrieval, or inherited custody transfers.
iPSCs are adult cells that have been reprogrammed in a laboratory into a pluripotent state. They can self-renew and may be directed to develop into many specialised cell types.
No. Adult cells, such as blood or skin cells, are collected first. These cells are then reprogrammed in a laboratory to generate iPSCs.
No. iPSC banking is a cell-generation and storage service. Any future treatment derived from those cells would require separate manufacturing, medical assessment and regulatory approval.
No. Reprogramming may be unsuccessful, or a generated line may not meet the required quality criteria. For further information about our cell banking guarantees, feel free to reach out to us.
